Lexicon Pharmaceuticals, Inc.（LXRX）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

57/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

75

Undervalued

動能

63

Gaining

情緒

55

Mixed

風險韌性

47

Elevated Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Michael S. Exton
上市以來: 2000年4月7日
僱員: 81

市場位置

日內區間

目前US$2.30，

US$2.195US$2.31

52週區間

目前US$2.30，

US$1.03US$2.68

開盤價: US$2.20
前收盤價: US$2.18
成交量: 319.48萬; 1.01× 平均值
平均成交量: 314.81萬; 日均成交量
市值: 10.22億 USD
貝塔: 1.04; 市場參考 1
50天平均值: US$2.2814; 高於平均水平+0.82%
200天平均值: US$1.7439; 高於平均水平+31.89%

財務數據

財務快照

估值與收益率

企業價值: 4.45億 USD
本益比（TTM）: -15.29×
股價淨值比（TTM）: 5.77×
股價營收比（TTM）: 24.64×
EV/EBITDA: -10.76×
盈餘收益率: -12.06%
自由現金流收益率: -16.25%
股息率: 0.00%

獲利能力和效率

毛利率: 98.85%
營業利益率: -131.43%
淨利潤率: -147.38%
股東權益報酬率: -46.81%
資產報酬率: -27.21%
投入資本報酬率: -28.71%

財務健康

負債權益比: 0.34×
流動比率: 4.88×
奧特曼 Z 分數: -3.02
皮奧特羅斯基 F 分數: 2 共 9 個

財報歷史與展望

EPS優於預期率: 73%; 優於預期8次、低於預期3次、符合預期0次
平均EPS意外幅度: +29.28%; 11 類似報告
最新每股收益結果: -0.06; 預估-0.05 · 低於預期19.45%

EPS：實際值與預估值

近期已公布業績

實際值預估值

營收：實際值與預估值

近期已公布業績

實際值預估值

最新財年每股收益: -0.14; 2025會計年度
最新財年收入: 4980.3萬 USD; 2025會計年度 · 年增+60.24%
下一財年每股收益共識: -0.166; 2026會計年度 · 3位分析師
下一財年營收共識: 3794.71萬 USD; 2026會計年度 · 4位分析師

年度每股收益趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

年度營收趨勢

已公布業績及可用的市場共識預估。

已公布市場共識預估

LXRX 訊息

seekingalpha.com2026年8月19日

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value…

閱讀原始碼

marketbeat.com2026年8月6日

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and…

閱讀原始碼

seekingalpha.com2026年8月6日

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

閱讀原始碼

zacks.com2026年8月6日

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.

閱讀原始碼

globenewswire.com2026年8月6日

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo…

閱讀原始碼

globenewswire.com2026年7月30日

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior…

閱讀原始碼